TG Therapeutics, Inc.

Healthcare · Biotechnology

Overall research band Weak

Quality Mixed

Valuation Very weak

Balance sheet Very weak

Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

TG Therapeutics, Inc. is a New York City-based biopharmaceutical company focused on acquiring, developing, and commercializing novel treatments for B-cell malignancies and autoimmune diseases. Its main products and investigational candidates include Ublituximab, a glycoengineered monoclonal antibody for B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing multiple sclerosis; Umbralisib, an oral inhibitor targeting PI3K-delta and CK1-epsilon for CLL, marginal zone lymphoma, and follicular lymphoma; Cosibelimab, a monoclonal antibody targeting PD-L1; TG-1701, a selective oral BTK inhibitor; and TG-1801, a bispecific antibody targeting CD47 and CD19. The company also has preclinical programs addressing BET, interleukin-1 receptor associated kinase-4, and GITR. TG Therapeutics generates revenue through the commercialization and licensing of its therapeutic products and maintains collaborations and strategic alliances with various pharmaceutical and biotechnology partners.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC16.2%Model input; read with the evidence status and period context.

Operating margin21.3%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years209.8%Model input; read with the evidence status and period context.

FCF margin-2.0%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.